Comparison between groups

Slides:

Advertisements

Similar presentations

Body Composition and Metabolic Changes in Antiretroviral-Naïve HIV-Infected Patients Randomized to Didanosine and Stavudine (ddI+d4T) vs. Abacavir and.

Advertisements

Click 98 bmi 1,75 kg m 98 bmi 1,75 kg m 32 Applet for calculation of body mass index.

Body Mass Index and Calorie. Body Mass Index Body Mass Index, or BMI, is a tool that helps you measure the amount of body fat you have based on your height.

A Randomised Double-Blind Study of Weight Reducing Effect and Safety of Rimonabant in Obese Patients with or without Comorbidities A Randomised Double-Blind.

Daily Trivia This little girl is sick. And sad .

Body Mass Index (BMI) This is the most commonly used index of over or underweight Body Mass Index = body weight ( Height) squared ClassificationBMI.

Adiponectinemia, glucose status, insulin secretion and insulin resistance in obese women: influence of weight loss 1) To compare variation in adiponectin.

WHAT IS BMI? BMI BODY MASS INDEX- BASED ON HEIGHT AND WEIGHT TO DETERMINE AMOUNT OF FAT AN INDIVIDUAL HAS OBESE BMI > 30.

Anthropometrics in Obesity Robert Kushner, MD Northwestern University Feinberg School of Medicine.

Whole Body Pethysmography H Measures body volume by air displacement –actually measures pressure changes with injection of known volume of air into closed.

Farid Saad Euro Weight Loss-2015 Frankfurt, Germany August 18 – 20, 2015.

 BSA (m 2 ) = √ Ht(in) X wt (lb) 3131 Ht (cm) X wt (kg) 3600 Mosteller,RD " Simplified Calculation of Body Surface Area", N Engl J Med 1987, 317 (17):

HDL LowLess than 40 mg/dL High60 mg/dL and above LDL OptimalLess than 100 mg/dL Near Optimal mg/dL Borderline High mg/dL High mg/dL.

Biological Relationship Between HIV and Nutrition Christine Wanke, MD AIDS Turning the Tide Together.

Slide Source: Lipids Online Slide Library ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing.

Ectomorph, Endomorph, and Mesomorph

Short Stature in Noonan Syndrome: Demography and Response to Growth Hormone Treatment in KIGS Barto J Otten KIGS 10 Year Book, 1999.

Males Females © Crown copyright and database rights 2012 Ordnance Survey Adult obesity: BMI ≥ 30kg/m 2.

Growth Hormone Treatment of Children with Prader-Willi Syndrome as Reported to KIGS: First-Year Growth Hormone E Martin Ritzén KIGS 10 Year Book, 1999.

School of Nursing, Midwifery and Social Work Malnutrition or poor body composition, particularly sarcopenia, may have a negative impact on clinical outcome.

analysed to establish the distribution of GJD2 SNPs T2D patients

Lacto-ovo vegetarian group

How to Calculate Your Body Mass Index (BMI)

Features of adult GH deficiency Improved by GH replacement?

Adverse Events - Demographics

0.24→0.37 mg/kg/week (▲) and 0.37 mg/kg/week ().

45-year-old woman with BMI of 23.1 and chest circumference of 94.0 cm. Axial CT images obtained at 120 kV and 200 mAs show ascending aorta with image noise.

Table 2. Changes in body composition, energy and water intake

ERT, estrogen replacement therapy

Updates on Policy #38 Addressing Subjects with Non-Average Heights and Weights 2017 SWOG Fall Meeting BOG Siu Fun Wong, PharmD Co-Chair, Pharmaceutical.

Answer the following questions:

Without insulin therapy (n = 14)

(A) Simulation of propofol effect-site concentrations (Ce) that result from a bolus (2 mg/kg) and 1-hour infusion (150 mcg/kg/min) for a 53-year-old 155-cm.

Fig. 2. Line diagrams of all individual patients depicting longitudinal changes of RM, body fat mass, visceral fat level, skeletal muscle mass, and caliper.

Clinical Aspects after Bariatric Procedures in Adolescent: Long Time Follow-Up Nicola Zampieri1, Roberto Castellani2, Marta Peretti1, Federica Bianchi1,

ارزیابی سریع وضعیت تغذیه در زنان میان سال سالم

Fluid retention symptoms Miscellaneous symptoms

Nutritional assessment in hospitalized patients

© The Author(s) Published by Science and Education Publishing.

GH peak (µg/l) Regression analysis of the GHRH+GHRP-6-elicited GH peaks plotted against body mass index (BMI), in 366 subjects with no endocrine pathology.

Table 1. General Characteristics of the Study Subjects

Achieving a Healthy Body Weight

© The Author(s) Published by Science and Education Publishing.

#significant difference versus baseline (P<.05).

Effects of 5 yr of GH substitution in 118 GH-deficient adults on serum concentrations of TC, HDL-C, LDL-C and TG as well as on blood glucose, serum insulin.

Bones mass (BMC) and standing height in patients with COGHD compared with normal Russian adults. All values are compared with results obtained.

Radiological Society of North America

Relationship between karyotype and basal characteristics at GH start

Life expectancy and baseline BP: Male participants

Visceral fat area (VFA, cm2), subcutaneous fat area (SFA, cm2), body mass index (BMI, kg/m2) and waist circumference (WC, cm) levels according to the quartiles.

Fig.1. The dose of GH administered to patients in different age groups after 1 year of GH replacement therapy. Data are shown as mean, median and 10th-90th.

No GH (n=19) Treated with GH (n=67) Mean (SD) Range Mean (SD) Range

GH dose 12 months of treatment 24 months of treatment Low Medium High

Body weight control and energy expenditure

 Height SDS  Weight SDS

Volume 63, Issue 5, Pages (May 2003)

 Gruppe A: 0,033mg WH/kg x die  Gruppe B: 0,067mg WH/kg x die

Height velocity (cm/yr) Height velocity (cm/yr)

Sensivity Sensivity Sensivity 100-specify 100-specify 100-specify

CI, confidence interval (95%)

Growth rate (cm/yr) Estrogen at age 12 Estrogen at age 15

Abbildung mod. nach Van Pareren, 2004

Change in LBM (%)‏ LD CD LD CD LD CD

Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study.

The correlation between visceral fat area (VFA) and body mass index (BMI) in patients with type 2 diabetes. The correlation between visceral fat area (VFA)

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

Angelo Cagnacci, M. D. , Ph. D. , Renata Zanin, M. D

--- 6-months’ therapy months’ therapy Supplementary Figure 1.

Fig. 3. Differences in the prevalence of albuminuria after comorbidity stratification. (A) Obesity defined by a body mass index ≥25 kg/m2, (B) central.

Presentation transcript:

Comparison between groups Anthropometric parameters and GH dose after 2 yr of GH therapy in patients with CP (n=183) and NFPA (n=209) Treatment effects after 2 yr (chance compared to baseline)a pb No. Mean ± SD Compared to baseline Comparison between groups GH dose (mg/d) Male CP NFPA Female 98 97 81 101 0.39 ± 0.21 0.39 ± 0.22 0.47 ± 0.26 0.49 ± 0.22 NA 0.90 0.10 Weight (kg) Male CP NFPA Female 96 101 87 108 2.50 ± 8.15 0.63 ± 5.96 3.36 ± 6.72 -0.31 ± 6.43 0.01 0.10 0.0001 0.88 0.36 0.001 Abbildung mod. nach Verhelst, 2005

Comparison between groups Anthropometric parameters and GH dose after 2 yr of GH therapy in patients with CP (n=183) and NFPA (n=209) Treatment effects after 2 yr (chance compared to baseline)a pb No. Mean ± SD Compared to baseline Comparison between groups BMI (kg/m2) Male CP NFPA Female 88 91 82 97 0.73 ± 2.11 0.17 ± 1.89 1.33 ± 2.68 -0.23 ± 2.41 0.004 0.20 0.0001 0.66 0.19 0.0002 Waist (cm) Male CP NFPA Female 64 71 63 78 -1.27 ± 5.64 -3.03 ± 5.23 2.45 ± 6.00 -2.06 ± 7.16 0.11 0.0001 0.003 0.02 0.06 0.0003 Abbildung mod. nach Verhelst, 2005

Comparison between groups Anthropometric parameters and GH dose after 2 yr of GH therapy in patients with CP (n=183) and NFPA (n=209) Treatment effects after 2 yr (chance compared to baseline)a pb No. Mean ± SD Compared to baseline Comparison between groups WHR Male CP NFPA Female 64 71 63 78 -0.02 ± 0.06 -0.02 ± 0.04 0.01 ± 0.05 -0.01 ± 0.06 0.02 0.0001 0.13 0.17 0.45 0.04 Fat mass (kg)c Male CP NFPA Female 24 21 22 20 -0.87 ± 6.07 -2.48 ± 6.72 2.36 ± 6.63 -3.02 ± 5.75 0.47 0.07 0.22 0.04 0.40 0.02 Abbildung mod. nach Verhelst, 2005

Comparison between groups Anthropometric parameters and GH dose after 2 yr of GH therapy in patients with CP (n=183) and NFPA (n=209) Treatment effects after 2 yr (chance compared to baseline)a pb No. Mean ± SD Compared to baseline Comparison between groups Fat-free mass (kg)c Male CP NFPA Female 24 21 20 3.10 ± 5.09 3.80 ± 6.30 2.10 ± 4.61 0.33 ± 3.31 0.007 0.01 0.03 0.60 0.69 0.17 BMI, Body mass index; NA, not applicable because no patient was taking GH at baseline a Information missing in several patients in both groups. b Wilcoxon rank-sum test (nonnormal distributet values) or t test (normal distributet values). c Only results from BIA. Abbildung mod. nach Verhelst, 2005